IL13 and Alzheimer disease: Dupilumab, the first biologic approved by the U.S. Food and Drug Administration in 2017 for moderate-to-severe AD, blocks interleukin 4 (IL-4) and IL-13 signaling by binding to interleukin 4 receptor α-antagonist, the shared receptor for both cytokines.1